235 related articles for article (PubMed ID: 33534142)
21. Bone marrow derived myeloid cells orchestrate antiangiogenic resistance in glioblastoma through coordinated molecular networks.
Achyut BR; Shankar A; Iskander AS; Ara R; Angara K; Zeng P; Knight RA; Scicli AG; Arbab AS
Cancer Lett; 2015 Dec; 369(2):416-26. PubMed ID: 26404753
[TBL] [Abstract][Full Text] [Related]
22. Pericytes in Glioblastomas: Multifaceted Role Within Tumor Microenvironments and Potential for Therapeutic Interventions.
Sattiraju A; Mintz A
Adv Exp Med Biol; 2019; 1147():65-91. PubMed ID: 31147872
[TBL] [Abstract][Full Text] [Related]
23. Programmed Cell Death 10 Mediated CXCL2-CXCR2 Signaling in Regulating Tumor-Associated Microglia/Macrophages Recruitment in Glioblastoma.
Zhang Q; Wang J; Yao X; Wu S; Tian W; Gan C; Wan X; You C; Hu F; Zhang S; Zhang H; Zhao K; Shu K; Lei T
Front Immunol; 2021; 12():637053. PubMed ID: 34108959
[TBL] [Abstract][Full Text] [Related]
24. Mechanism and therapeutic potential of tumor-immune symbiosis in glioblastoma.
Pang L; Khan F; Heimberger AB; Chen P
Trends Cancer; 2022 Oct; 8(10):839-854. PubMed ID: 35624002
[TBL] [Abstract][Full Text] [Related]
25. Harnessing the cross-talk between tumor cells and tumor-associated macrophages with a nano-drug for modulation of glioblastoma immune microenvironment.
Li TF; Li K; Wang C; Liu X; Wen Y; Xu YH; Zhang Q; Zhao QY; Shao M; Li YZ; Han M; Komatsu N; Zhao L; Chen X
J Control Release; 2017 Dec; 268():128-146. PubMed ID: 29051064
[TBL] [Abstract][Full Text] [Related]
26. Macrophages and microglia in glioblastoma: heterogeneity, plasticity, and therapy.
Khan F; Pang L; Dunterman M; Lesniak MS; Heimberger AB; Chen P
J Clin Invest; 2023 Jan; 133(1):. PubMed ID: 36594466
[TBL] [Abstract][Full Text] [Related]
27. Changes in the tumor microenvironment and outcome for TME-targeting therapy in glioblastoma: A pilot study.
Ali S; Borin TF; Piranlioglu R; Ara R; Lebedyeva I; Angara K; Achyut BR; Arbab AS; Rashid MH
PLoS One; 2021; 16(2):e0246646. PubMed ID: 33544755
[TBL] [Abstract][Full Text] [Related]
28. Pharmacological targeting of the tumor-immune symbiosis in glioblastoma.
Pang L; Khan F; Dunterman M; Chen P
Trends Pharmacol Sci; 2022 Aug; 43(8):686-700. PubMed ID: 35534356
[TBL] [Abstract][Full Text] [Related]
29. The N
Zhao R; Li B; Zhang S; He Z; Pan Z; Guo Q; Qiu W; Qi Y; Zhao S; Wang S; Chen Z; Zhang P; Guo X; Xue H; Li G
Front Immunol; 2021; 12():653711. PubMed ID: 34354698
[TBL] [Abstract][Full Text] [Related]
30. Targeting CXCR4 by a selective peptide antagonist modulates tumor microenvironment and microglia reactivity in a human glioblastoma model.
Mercurio L; Ajmone-Cat MA; Cecchetti S; Ricci A; Bozzuto G; Molinari A; Manni I; Pollo B; Scala S; Carpinelli G; Minghetti L
J Exp Clin Cancer Res; 2016 Mar; 35():55. PubMed ID: 27015814
[TBL] [Abstract][Full Text] [Related]
31. Interactions between tumor-associated macrophages and tumor cells in glioblastoma: unraveling promising targeted therapies.
Morisse MC; Jouannet S; Dominguez-Villar M; Sanson M; Idbaih A
Expert Rev Neurother; 2018 Sep; 18(9):729-737. PubMed ID: 30099909
[TBL] [Abstract][Full Text] [Related]
32. Increased Antiangiogenic Effect by Blocking CCL2-dependent Macrophages in a Rodent Glioblastoma Model: Correlation Study with Dynamic Susceptibility Contrast Perfusion MRI.
Cho HR; Kumari N; Thi Vu H; Kim H; Park CK; Choi SH
Sci Rep; 2019 Jul; 9(1):11085. PubMed ID: 31366997
[TBL] [Abstract][Full Text] [Related]
33. Revealing and Harnessing Tumour-Associated Microglia/Macrophage Heterogeneity in Glioblastoma.
Pires-Afonso Y; Niclou SP; Michelucci A
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 31973030
[No Abstract] [Full Text] [Related]
34. Single-Cell Transcriptome Profiling Signatures and Alterations of Microglia Associated With Glioblastoma Associate Microglia Contribution to Tumor Formation.
Xia H; Deng L; Meng S; Liu X; Zheng C
Pathol Oncol Res; 2022; 28():1610067. PubMed ID: 35693633
[TBL] [Abstract][Full Text] [Related]
35. Role of myeloid cells in the immunosuppressive microenvironment in gliomas.
Locarno CV; Simonelli M; Carenza C; Capucetti A; Stanzani E; Lorenzi E; Persico P; Della Bella S; Passoni L; Mavilio D; Bonecchi R; Locati M; Savino B
Immunobiology; 2020 Jan; 225(1):151853. PubMed ID: 31703822
[TBL] [Abstract][Full Text] [Related]
36. Microglia-Centered Combinatorial Strategies Against Glioblastoma.
Martins TA; Schmassmann P; Shekarian T; Boulay JL; Ritz MF; Zanganeh S; Vom Berg J; Hutter G
Front Immunol; 2020; 11():571951. PubMed ID: 33117364
[TBL] [Abstract][Full Text] [Related]
37. Local Targeting of NAD
Li M; Kirtane AR; Kiyokawa J; Nagashima H; Lopes A; Tirmizi ZA; Lee CK; Traverso G; Cahill DP; Wakimoto H
Cancer Res; 2020 Nov; 80(22):5024-5034. PubMed ID: 32998997
[TBL] [Abstract][Full Text] [Related]
38. A Virus-Mimicking Nucleic Acid Nanogel Reprograms Microglia and Macrophages for Glioblastoma Therapy.
Gao X; Li S; Ding F; Liu X; Wu Y; Li J; Feng J; Zhu X; Zhang C
Adv Mater; 2021 Mar; 33(9):e2006116. PubMed ID: 33501743
[TBL] [Abstract][Full Text] [Related]
39. EnLIGHTenment of tumor vessel normalization and immunotherapy in glioblastoma.
Treps L
J Pathol; 2018 Sep; 246(1):3-6. PubMed ID: 29876930
[TBL] [Abstract][Full Text] [Related]
40. Pericytes Are Immunoregulatory Cells in Glioma Genesis and Progression.
Martinez-Morga M; Garrigos D; Rodriguez-Montero E; Pombero A; Garcia-Lopez R; Martinez S
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791110
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
